|Day's Range||210.24 - 214.25|
|52 Week Range||136.53 - 214.25|
|PE Ratio (TTM)||43.83|
|Dividend & Yield||1.36 (0.64%)|
|1y Target Est||N/A|
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.